Poly(ADP‐ribose)polymerase inhibitors‐associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres.

MLA

Morice, Pierre‐Marie, et al. “Poly(ADP‐ribose)Polymerase Inhibitors‐associated Myeloid Neoplasms: A Retrospective Study from the French Network of Pharmacovigilance Centres.” British Journal of Haematology, vol. 196, no. 3, Feb. 2022, pp. 787–93. EBSCOhost, https://doi.org/10.1111/bjh.17863.

APA

Morice, P., Genthon, A., Boyer, T., Bihan, K., Mahé, J., Sourisseau, A., Peyrouzet, H., Miremont, G., Lepelley, M., Stefani, L., Gaboriau, L., Rocher, F., Aquaronne, D., Le Beller, C., Allouchery, M., Azzouz, B., Massy, N., Alt, T. M., Simand, C., & Herbrecht, R. (2022). Poly(ADP‐ribose)polymerase inhibitors‐associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres. British Journal of Haematology, 196(3), 787–793. https://doi.org/10.1111/bjh.17863

Chicago

Morice, Pierre‐Marie, Alexis Genthon, Thomas Boyer, Kevin Bihan, Julien Mahé, Anthony Sourisseau, Hélène Peyrouzet, et al. 2022. “Poly(ADP‐ribose)Polymerase Inhibitors‐associated Myeloid Neoplasms: A Retrospective Study from the French Network of Pharmacovigilance Centres.” British Journal of Haematology 196 (3): 787–93. doi:10.1111/bjh.17863.